News Background

Oxford, UK – 16 July 2015. OGT, The Molecular Genetics Company, has made its European Human Genetics (ESHG) Conference workshop freely available to view online. The presentation, entitled ‘The Next Generation of Microarrays: Identifying a Broader Range of Genetic Syndromes Using Exon–Focussed Array Designs’, took place at the ESHG conference in Glasgow, UK on 8th June 2015. OGT also launched its CytoSure® Constitutional v3 Arrays at the event.

Having become one of the premier events in the field of human genetics, ESHG is a forum for all workers in human and medical genetics to review the latest advances and develop research collaborations. OGT’s workshop was one of the best attended workshops of the conference, with over 150 delegates turning up to learn how OGT has coupled its microarray design expertise with the latest developmental disorder content to create CytoSure Constitutional v3 arrays. Launched at the ESHG conference, these are the only arrays available with enhanced content from the Deciphering Developmental Disorders (DDD) study1,2 and ClinGen (formerly ISCA/ICCG) — enabling high-resolution CNV detection across ~500 genes of interest.

Senior Computational Biologist at OGT, Duarte Molha, discussed OGT’s advanced microarray design strategies to deliver the latest generation of exon-focused arrays for the accurate detection of small DNA deletions and duplications. In addition, Professor Madhuri Hegde PhD, FACMG, Professor of Human Genetics at Emory University School of Medicine presented how Emory University complements its next generation sequencing workflows with OGT’s CytoSure Medical Research Exome array to provide gold-standard CNV detection at the exon level.

 

References

  1. Large-scale discovery of novel genetic causes of developmental disorders. The Deciphering Developmental Disorders Study. Fitzgerald, T.W. et al, Nature 519, 223–228 (12 March 2015)
  2. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. Fitzgerald, T.W. et al, The Lancet 385, No. 9975, p1305–1314, (4 April 2015)
  3. About OGT

    OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.

     

    For more information on the Company, please visit our website at ogt.com

     

    CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell: Some products may not be available in your region.

     

    About Sysmex Corporation

    Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

     

    For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.

You might also be interested in

OGT launches breakthrough NGS panel for constitutional cytogenetics Listing Image

OGT launches breakthrough NGS panel for constitutional cytogenetics

30 Jan 2020

Robust panel enables accurate and comprehensive constitutional genetic aberration screening in one assay.

Read
OGT develops transformative constitutional NGS panel Listing Image

OGT develops transformative constitutional NGS panel

10 Dec 2019

CytoSure™ NGS – Combining the benefits of microarrays and NGS in a single assay.

Read
NHS study confirms higher reporting rate for OGT's CytoSure v3 array Listing Image

NHS study confirms higher reporting rate for OGT's CytoSure v3 array

22 Jul 2020

Paper published in npj Genomic Medicine demonstrates identification of more reportable CNVs with CytoSure v3 vs traditional array design.

Read
All News
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter